Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Expanding US operations to address the increased demand for API development and manufacturing
This new facility strengthens Latin America as a collaborative hub
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Subscribe To Our Newsletter & Stay Updated
